Video by PCR via YouTube
Go to Source

Mirvat Alasnag interviews Nicolas M. Van Mieghem about the results of the TAVR UNLOAD trial he presented at the TCT Conference 2024. TAVR for moderate AS in Heart Failure with reduced Ejection Fraction (HFrEF) patients on GDMT was safe and improved quality of life at one year but didn’t affect the primary endpoint at 23 months. ​
The study faced limitations like slow enrollment, design changes, and higher-than-expected TAVR need in the surveillance group, impacting results.

More news about the TCT 2024 on PCRonline: https://www.pcronline.com/News/Whats-new-on-PCRonline/2024/TCT/PCRonline-at-TCT-2024

#heartfailure #tavr

Go to Source